BOLDER BIOTECHNOLOGY AWARDED NIH GRANT TO DEVELOP NOVEL ARTHRITIS TREATMENT

Bolder BioTechnology has been awarded a $100,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of NIH. The grant supports research to optimize a human protein to enhance its ability to inhibit formation of new blood vessels, which may provide a novel approach for the treatment of rheumatoid arthritis.

Denver dBusinessNews (http://denver.dbusinessnews.com/shownews.php?type_news=latest&newsid=8769)